Investor Seeks To Block DSM's $360M Kensey Nash Buyout
Lead plaintiff Hilary Conye claims Kensey Nash’s agreed-upon sales price of $38.50 per share is "woefully inadequate" and is a product of a flawed process designed to ensure the sale of the company on preferential terms to DSM at the expense of shareholders.
"Kensey Nash represents a highly attractive acquisition candidate," the complaint...
Already a subscriber? Click here to login